191 related articles for article (PubMed ID: 35137467)
1. Changing opportunities for liver transplant for patients with hepatocellular carcinoma.
Zendel A; Watkins R; Moon AM; Gerber DA; Barritt AS; Desai CS
Clin Transplant; 2022 May; 36(5):e14609. PubMed ID: 35137467
[TBL] [Abstract][Full Text] [Related]
2. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH; Chyou D; Goldberg DS
Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
[TBL] [Abstract][Full Text] [Related]
3. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma.
Mazur RD; Cron DC; Chang DC; Yeh H; Dageforde LAD
Transplantation; 2024 Jan; 108(1):204-214. PubMed ID: 37189232
[TBL] [Abstract][Full Text] [Related]
4. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses.
Wey A; Noreen S; Gentry S; Cafarella M; Trotter J; Salkowski N; Segev D; Israni A; Kasiske B; Hirose R; Snyder J
Liver Transpl; 2022 Mar; 28(3):363-375. PubMed ID: 34482614
[TBL] [Abstract][Full Text] [Related]
7. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
Taniguchi M
Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
[TBL] [Abstract][Full Text] [Related]
9. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
Yao FY; Bass NM; Ascher NL; Roberts JP
Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
[TBL] [Abstract][Full Text] [Related]
11. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
[TBL] [Abstract][Full Text] [Related]
12. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
13. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
14. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis.
Vitale A; Saracino E; D'Amico FE; Grigoletto F; Burra P; Angeli P; Boccagni P; Brolese A; Zanus G; Neri D; Gringeri E; D'Amico F; Valmasoni M; Carraro A; Gambato M; Feltracco P; Romano A; Buggio M; D'Amico DF; Cillo U
Transplant Proc; 2009 May; 41(4):1092-5. PubMed ID: 19460489
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.
Wiesner RH; Freeman RB; Mulligan DC
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S261-7. PubMed ID: 15508092
[TBL] [Abstract][Full Text] [Related]
17. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
18. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
Samoylova ML; Dodge JL; Mehta N; Yao FY; Roberts JP
Clin Transplant; 2015 Jan; 29(1):52-9. PubMed ID: 25366656
[TBL] [Abstract][Full Text] [Related]
20. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
Hayashi PH; Trotter JF; Forman L; Kugelmas M; Steinberg T; Russ P; Wachs M; Bak T; Kam I; Everson GT
Liver Transpl; 2004 Jan; 10(1):42-8. PubMed ID: 14755776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
